Evidence map›Paper›PMID 31332062›Full record

ArticleAntimicrobial agents and chemotherapy2019

Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.

Anthony Enimil, Sampson Antwi, Hongmei Yang, Albert Dompreh, Wael A Alghamdi, Fizza S Gillani, Antoinette Orstin, Dennis Bosomtwe, Theresa Opoku, Jennifer Norman and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021
    Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Anthony Enimil *Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Sampson Antwi *Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Hongmei YangDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Albert DomprehDirectorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Wael A AlghamdiDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.ORCID 0000-0002-4484-6994
Fizza S GillaniDepartment of Medicine, The Miriam Hospital, Providence, Rhode Island, USA.
Antoinette OrstinDirectorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Dennis BosomtweDirectorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Theresa OpokuDirectorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Jennifer NormanDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-9070-8699
Taimour LangaeeDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Charles A PeloquinDepartment of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.ORCID 0000-0001-9002-7052
Michael H CourtProgram in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.
David J GreenblattGraduate Program in Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.
Awewura KwaraDepartment of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA awewura.kwara@medicine.ufl.edu.ORCID 0000-0002-1118-8331
Komfo Anokye Teaching Hospital · GHUniversity of Florida · USUniversity of Cape Town · ZAProvidence College · USTufts University · USUniversity of Rochester · USWashington State University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in ChildrenR01HD071779 · NICHD · UNIVERSITY OF FLORIDA · PI KWARA, AWEWURA JACOB · 2012 to 2022
$6.0M
MicroRNAs as effectors of variable human drug metabolismR01GM102130 · NIGMS · WASHINGTON STATE UNIVERSITY · PI COURT, MICHAEL H · 2012 to 2015
$1.1M
NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI078498NIAID NIH HHS U01 AI068632NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NICHD NIH HHS R01 HD071779NIGMS NIH HHS R01 GM102130
6 · The paper itself

Abstract

Nevirapine-based antiretroviral therapy (ART) is one of the limited options in HIV-infected children younger than 3 years old (young children) with tuberculosis (TB) coinfection. To date, there are insufficient data to recommend nevirapine-based therapy during first-line antituberculosis (anti-TB) therapy in young children. We compared nevirapine pharmacokinetics (PK) in HIV-infected young children with and without TB coinfection. In the coinfected group, nevirapine PK was evaluated while on anti-TB therapy and after completing an anti-TB therapy regimen. Of 53 participants, 23 (43%) had TB-HIV coinfection. While the mean difference in nevirapine PK parameters between the two groups was not significant (

Indexed as

Anti-HIV AgentsAntitubercular AgentsChild, PreschoolCoinfectionCytochrome P-450 CYP2B6FemaleGenotypeHIV InfectionsHumansInfantMaleNevirapineTuberculosisAnti-HIV AgentsAntitubercular AgentsCytochrome P-450 CYP2B6NevirapinechildrencoinfectionCYP2B6 genotypehuman immunodeficiency virusnevirapinepharmacokineticstuberculosis

Identifiers

PMID31332062
PMCPMC6761507
OpenAlexW2963949057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.